Overview

A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
This study will evaluate efficacy, safety and tolerability of Avastin versus placebo added to a chemotherapeutic regimen in patients with metastatic pancreatic cancer. The anticipated time of study treatment is until confirmed evidence of disease progression, and the target sample size is 500+ individuals.
Phase:
Phase 3
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Bevacizumab